Drupacine as a potent SARS-CoV-2 replication inhibitor in vitro
Open Access
- 3 September 2024
- journal article
- research article
- Published by Elsevier in Biosafety and Health
- Vol. 6 (5) , 270-278
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 65 references indexed in Scilit:
- High content screening strategies for large-scale compound libraries with a focus on high-containment virusesAntiviral Research, 2023
- Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron VariantJAMA, 2022
- Targeting papain-like protease for broad-spectrum coronavirus inhibitionProtein & Cell, 2022
- Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care WorkersJAMA Internal Medicine, 2021
- Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold CoronavirusesCell, 2021
- A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2Antiviral Research, 2021
- The Global Phosphorylation Landscape of SARS-CoV-2 InfectionCell, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Synergistic drug combination effectively blocks Ebola virus infectionAntiviral Research, 2017
- Nematotoxicity of drupacine and a Cephalotaxus alkaloid preparation against the plant‐parasitic nematodes Meloidogyne incognita and Bursaphelenchus xylophilusPest Management Science, 2013